Evidence map›Paper›PMID 42871639›Full record

ArticleACS pharmacology & translational science2026

Integrated

Pankaj Kumar, Zahid Bashir Zargar, Suraj Pratap Singh, Kushvinder Kumar, Binita Sihag, Shubham Debaje, Abhay T Sangamwar, Pavitra Ranawat, Gurpal Singh, Ravi Pratap Barnwal and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in ACS pharmacology & translational science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Pankaj KumarUniversity Institute of Pharmaceutical Sciences, Panjab University, Chandigarh 160014, India.ORCID https://orcid.org/0009-0000-4596-7539
Zahid Bashir ZargarUniversity Institute of Pharmaceutical Sciences, Panjab University, Chandigarh 160014, India.
Suraj Pratap SinghDepartment of Biophysics, Panjab University, Chandigarh 160014, India.
Kushvinder KumarDepartment of Chemistry and Centre of Advanced Studies, Panjab University, Chandigarh 160014, India.
Binita SihagDepartment of Chemistry and Centre of Advanced Studies, Panjab University, Chandigarh 160014, India.
Shubham DebajeDepartment of Pharmaceutics, National Institute of Pharmaceutical Education and Research, SAS Nagar, Punjab 160062, India.
Abhay T SangamwarDepartment of Pharmaceutics, National Institute of Pharmaceutical Education and Research, SAS Nagar, Punjab 160062, India.ORCID https://orcid.org/0000-0002-0259-9956
Pavitra RanawatDepartment of Biophysics, Panjab University, Chandigarh 160014, India.
Gurpal SinghUniversity Institute of Pharmaceutical Sciences, Panjab University, Chandigarh 160014, India.ORCID https://orcid.org/0000-0003-1665-145X
Ravi Pratap BarnwalDepartment of Biophysics, Panjab University, Chandigarh 160014, India.
Deepak B SalunkeDepartment of Chemistry and Centre of Advanced Studies, Panjab University, Chandigarh 160014, India.
Sandip V PawarUniversity Institute of Pharmaceutical Sciences, Panjab University, Chandigarh 160014, India.ORCID https://orcid.org/0000-0003-4886-1435

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Toll-like receptors (TLRs) are key pattern recognition receptors that play a central role in regulating and bridging both innate and adaptive immune responses. Notably, TLR7 and TLR8 agonists have gained significant attention as promising therapeutic candidates because of their ability to activate immune responses and modulate immune signaling pathways for treating viral infections, autoimmune disorders, and cancer. Despite the growing interest in the area of immunotherapy, there remains a substantial gap in the development of new immunomodulators with improved efficacy and safety profiles. The primary objective of the study was to identify and evaluate newly synthesized TLR7/8 agonists using integrated

Indexed as

colorectal cancerMD simulationmolecular dockingnetwork pharmacologyTLR7/8 agonists

Identifiers

PMID42871639
PMCPMC13659847

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.